Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC).
The aim of this study was to develop nanostructured lipid carriers (NLC) for topical delivery of fluticasone propionate (FP) with the aim to further improve the safety profile and decrease the adverse-side effects commonly reported in topical corticotherapy. NLC are colloidal drug-carriers consisting of a blend of a solid lipid and a small amount of liquid lipid since these carriers have proved to be effective in epidermal targeting in particular of glucocorticoids. NLC consisting of glyceryl palmito-stearate, and PEG-containing medium chain triglycerides mixture, stabilised by polysorbate 80 and soybean phosphatidylcholine were prepared. A mean particle size between 380 and 408 nm and entrapment efficacy of 95% were obtained for FP-loaded NLC. The crystallinity and polymorphic phase behaviour of FP-free and FP-loaded NLC were examined by differential scanning calorimetry and wide angle X-ray diffraction. Results revealed a low-crystalline structure and confirmed the incorporation of FP into the particles. The suitability of PEG-containing liquid lipids to form the lipid matrix of NLC was also confirmed.
Doktorovová
Slavomíra
S
Fernando Pessoa University, Faculty of Health Sciences, Rua Carlos da Maia 296, P-4300-150 Porto, Portugal.
Araújo
Joana
J
Garcia
Marisa L
ML
Rakovský
Erik
E
Souto
Eliana B
EB
D000730:Androstadienes / Q000737:chemistry*; D002152:Calorimetry, Differential Scanning; D003460:Crystallization; D004337:Drug Carriers / Q000737:chemistry*; D004339:Drug Compounding; D000068298:Fluticasone; D008055:Lipids / Q000737:chemistry*; D049329:Nanostructures / Q000737:chemistry*; D010316:Particle Size; D011092:Polyethylene Glycols / Q000737:chemistry*; D013057:Spectrum Analysis; D014961:X-Ray Diffraction
D000730:Androstadienes; D004337:Drug Carriers; D008055:Lipids; D011092:Polyethylene Glycols; D000068298:Fluticasone